Drugs / Granulocytes
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06240767 | Nov 2023 → Jun 2025 | cancer | Wuxi People's Hospital | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07372885 | Feb 2026 → Dec 2028 expected | acute myeloid leukemia | University of Manchester | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04124666 | Dec 2019 → Sep 2022 | cancer of unknown primary site | Shanghai East Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05425043 | Sep 2021 → Jun 2026 overdue | childhood malignant neoplasm | University of Manchester | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | granulocytes | “The number of single granulocytes per infusion was 2.0-5.0×10\^10, with an interval of 2±1 day and 5 continuous infusions.” NCT06240767 ↗ |
| Modality | Cell therapy | “healthy donor granulocytes with high cancer-killing activity are collected and infused” NCT04124666 ↗ |